Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3a/3b CKD
ConclusionsBexagliflozin reduces hemoglobin A1c levels in patients with diabetes and stage 3a/3b CKD and appears to be well tolerated. Additional observed benefits included reductions in body weight, systolic blood pressure, and albuminuria.FundingTrial was sponsored by Theracos Sub, LLC.
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
More News: Cardiology | Cardiovascular | Chronic Kidney Disease | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Heart | SGLT2 Inhibitors | Sodium | Study | Urology & Nephrology